BioCardia, Inc. (BCDA)

$2.05

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol BCDA
Price $2.05
Beta 1.227
Volume Avg. 0.06M
Market Cap 34.451M
Shares () -
52 Week Range 1.1-3.09
1y Target Est -
DCF Unlevered BCDA DCF ->
DCF Levered BCDA LDCF ->
ROE -126.57% Strong Sell
ROA -106.42% Strong Sell
Operating Margin -
Debt / Equity 67.30% Buy
P/E -
P/B 5.37 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BCDA news


Dr. Peter Altman
Healthcare
Biotechnology
NASDAQ Capital Market

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.